Fangsheng Pharmaceutical released its 2026 interim report. In the first half, net profit attributable to the parent rose 16.8% year on year to 198 million yuan, while operating revenue grew 14.8% to 958 million yuan. In the second quarter, operating revenue increased 18.9% year on year to 495 million yuan, and net profit attributable to the parent climbed 34.9% to 109 million yuan. As of the end of the second quarter, total assets stood at 3.092 billion yuan, up 1.2% from the end of the previous year, and net assets attributable to the parent reached 1.777 billion yuan, up 3.8%. The company said its main business has not undergone major changes, and it remains focused on pharmaceutical research and development, production and sales, with products covering cardiovascular and cerebrovascular, musculoskeletal, and pediatric medicines. Through refined management and cost reduction and efficiency improvement, it achieved growth in both revenue and net profit.
Hunan Fangsheng Pharm Co LtdFirst-half net profit attributable to parent rose 16.8% to 198 million yuan, with revenue up 14.8%.